204 related articles for article (PubMed ID: 9364873)
1. [Successful treatment for advanced and refractory chronic lymphocytic leukemia with fludarabine phosphate].
Takeuchi M; Tada A; Soda R; Takahashi K
Rinsho Ketsueki; 1997 Sep; 38(9):792-4. PubMed ID: 9364873
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia.
Faderl S; Rai K; Gribben J; Byrd JC; Flinn IW; O'Brien S; Sheng S; Esseltine DL; Keating MJ
Cancer; 2006 Sep; 107(5):916-24. PubMed ID: 16832816
[TBL] [Abstract][Full Text] [Related]
3. Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population.
Perkins JG; Flynn JM; Howard RS; Byrd JC
Cancer; 2002 Apr; 94(7):2033-9. PubMed ID: 11932906
[TBL] [Abstract][Full Text] [Related]
4. Oral fludarabine treatment of cutaneous infiltration in a patient with B-cell chronic lymphocytic leukaemia.
Ural AU; Kubar A; Avcu F; Tastan HB; Safali M; Nevruz O; Cetin T
Clin Exp Dermatol; 2007 Mar; 32(2):151-4. PubMed ID: 17244344
[TBL] [Abstract][Full Text] [Related]
5. [Successful treatment with fludarabine of chronic lymphocytic leukemia associated with nephrotic syndrome].
Takei K; Horikoshi A; Hosokawa Y; Sawada S; Horie T
Rinsho Ketsueki; 2002 Nov; 43(11):993-7. PubMed ID: 12508485
[TBL] [Abstract][Full Text] [Related]
6. Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia.
Tsimberidou AM; Keating MJ; Giles FJ; Wierda WG; Ferrajoli A; Lerner S; Beran M; Andreeff M; Kantarjian HM; O'Brien S
Cancer; 2004 Jun; 100(12):2583-91. PubMed ID: 15197800
[TBL] [Abstract][Full Text] [Related]
7. Low-dose fludarabine and cyclophosphamide in elderly patients with B-cell chronic lymphocytic leukemia refractory to conventional therapy.
Marotta G; Bigazzi C; Lenoci M; Tozzi M; Bocchia M; Lauria F
Haematologica; 2000 Dec; 85(12):1268-70. PubMed ID: 11114133
[TBL] [Abstract][Full Text] [Related]
8. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia.
O'Brien S; Moore JO; Boyd TE; Larratt LM; Skotnicki A; Koziner B; Chanan-Khan AA; Seymour JF; Bociek RG; Pavletic S; Rai KR
J Clin Oncol; 2007 Mar; 25(9):1114-20. PubMed ID: 17296974
[TBL] [Abstract][Full Text] [Related]
9. [Long-term results with fludarabine monotherapy in chronic lymphocytic leukemia].
Varga F; Lehoczky D; Demeter J
Orv Hetil; 1999 Aug; 140(31):1731-5. PubMed ID: 10463032
[TBL] [Abstract][Full Text] [Related]
10. Therapy-related acute myeloid leukemia after single-agent treatment with fludarabine for chronic lymphocytic leukemia.
Lam CC; Ma ES; Kwong YL
Am J Hematol; 2005 Aug; 79(4):288-90. PubMed ID: 16044456
[TBL] [Abstract][Full Text] [Related]
11. [Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) are elevated in peripheral blood plasma of patients with chronic lymphocytic leukemia and decrease after intensive fludarabine-based treatment].
Smolej L; Andrýs C; Krejsek J; Belada DZ; Zák P; Siroký O; Malý J
Vnitr Lek; 2007 Nov; 53(11):1171-6. PubMed ID: 18277626
[TBL] [Abstract][Full Text] [Related]
12. High-dose methylprednisolone can induce remissions in patients with fludarabine-refractory chronic lymphocytic leukaemia.
Xu W; Miao KR; Hong M; Zhu DX; Fang C; Dong HJ; Wang DM; Cao X; Li JY
Eur J Cancer; 2010 Aug; 46(12):2145-9. PubMed ID: 20627536
[TBL] [Abstract][Full Text] [Related]
13. Pentostatin (Nipent) and chlorambucil with granulocyte-macrophage colony-stimulating factor support for patients with previously untreated, treated, and fludarabine-refractory B-cell chronic lymphocytic leukemia.
Waselenko JK; Grever MR; Beer M; Lucas MA; Byrd JC
Semin Oncol; 2000 Apr; 27(2 Suppl 5):44-51. PubMed ID: 10877052
[TBL] [Abstract][Full Text] [Related]
14. 2-Chlorodeoxyadenosine (2-CdA) in chronic lymphocytic leukemia refractory to fludarabine?
Schirmer M; Michlmayr G; Geisen F; Konwalinka G
Leukemia; 1996 Jul; 10(7):1253-4. PubMed ID: 8684013
[No Abstract] [Full Text] [Related]
15. [Successful combined treatment with rituximab and high dose immunoglobulin in a patient with chronic lymphocytic leukemia with fludarabine-induced severe immune thrombocytopenia].
Telek B; Batár P; Uvardy M
Orv Hetil; 2005 Aug; 146(34):1791-3. PubMed ID: 16184881
[TBL] [Abstract][Full Text] [Related]
16. High dose methylprednisolone and rituximab is an effective therapy in advanced refractory chronic lymphocytic leukemia resistant to fludarabine therapy.
Dungarwalla M; Evans SO; Riley U; Catovsky D; Dearden CE; Matutes E
Haematologica; 2008 Mar; 93(3):475-6. PubMed ID: 18310545
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of DT fusion protein denileukin diftitox in patients with fludarabine-refractory chronic lymphocytic leukemia.
Frankel AE; Fleming DR; Hall PD; Powell BL; Black JH; Leftwich C; Gartenhaus R
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3555-61. PubMed ID: 14506141
[TBL] [Abstract][Full Text] [Related]
18. Engagement of alpha4beta1 integrin by fibronectin induces in vitro resistance of B chronic lymphocytic leukemia cells to fludarabine.
de la Fuente MT; Casanova B; Moyano JV; Garcia-Gila M; Sanz L; Garcia-Marco J; Silva A; Garcia-Pardo A
J Leukoc Biol; 2002 Mar; 71(3):495-502. PubMed ID: 11867687
[TBL] [Abstract][Full Text] [Related]
19. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia.
Tsimberidou AM; Wierda WG; Plunkett W; Kurzrock R; O'Brien S; Wen S; Ferrajoli A; Ravandi-Kashani F; Garcia-Manero G; Estrov Z; Kipps TJ; Brown JR; Fiorentino A; Lerner S; Kantarjian HM; Keating MJ
J Clin Oncol; 2008 Jan; 26(2):196-203. PubMed ID: 18182662
[TBL] [Abstract][Full Text] [Related]
20. 2-Chlorodeoxyadenosine for patients with B-cell chronic lymphocytic leukemia resistant to fludarabine.
Saven A; Lemon RH; Piro LD
N Engl J Med; 1993 Mar; 328(11):812-3. PubMed ID: 8094889
[No Abstract] [Full Text] [Related]
[Next] [New Search]
